GlassScriptPhysician profile
Sergio F Rovner
NPI 1437164803
$645,695.43
in general payments reported to CMS, 2019-2025
70 companies · $102K in 2025
The $102K reported for 2025 was more than what 98% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $141K · 2020: $62K · 2021: $60K · 2022: $92K · 2023: $90K · 2024: $98K · 2025: $102K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $204K · Honoraria: $34K · Food and Beverage: $24K · Travel and Lodging: $11K · Consulting Fee: $9,844 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $8,426 · Education: $77.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $203,500.25 |
| Honoraria | $33,836.00 |
| Food and Beverage | $24,060.30 |
| Travel and Lodging | $10,808.21 |
| Consulting Fee | $9,843.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $8,426.00 |
| Education | $77.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $217,333.90 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $98,809.21 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Corcept Therapeutics | $55,068.73 | 2019-2025 | Korlym |
| Amgen INC. | $38,746.13 | 2019-2025 | Tepezza, Repatha, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36,210.99 | 2019-2025 | Jardiance, Synjardy |
| Sanofi-Aventis U.S. LLC | $33,730.48 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $31,894.91 | 2019-2025 | Farxiga |
| Horizon Therapeutics Plc | $29,129.53 | 2019-2023 | Tepezza |
| Bayer Healthcare Pharmaceuticals INC. | $28,944.06 | 2021-2025 | |
| Amarin Pharma, INC. | $21,056.32 | 2019-2022 | |
| Dexcom, INC. | $11,702.05 | 2020-2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Novo Nordisk As | $10,086.17 | 2019 | |
| Janssen Pharmaceuticals, INC | $8,504.31 | 2019-2022 | |
| Esperion Therapeutics, INC. | $4,783.20 | 2020-2025 | Nexletol |
| Abbott Laboratories | $4,713.94 | 2019-2025 | Freestyle Libre 3 |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $2,276.84 | 2019-2024 | Belsomra, Steglatro, Gardasil 9 |
| Medtronic Minimed, INC. | $1,343.98 | 2019-2020 | |
| Recordati_rare_diseases_inc. | $1,257.36 | 2021-2025 | Isturisa, Signifor Lar |
| Insulet Corporation | $1,249.86 | 2019-2025 | Omnipod |
| Abbvie INC. | $1,050.80 | 2019-2025 | Ubrelvy, Synthroid |
| Radius Health, INC. | $855.48 | 2019-2025 | Tymlos |
| Novartis Pharmaceuticals Corporation | $692.61 | 2022-2025 | |
| Xeris Pharmaceuticals, INC. | $643.37 | 2020-2025 | Recorlev, Gvoke Hypopen |
| Medtronic, INC. | $594.42 | 2021-2025 | Minimed 780g, Intellis Adaptivestim |
| Tandem Diabetes Care, INC. | $535.98 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Antares Pharma, INC. | $428.73 | 2020-2025 | Xyosted, Tlando, Nocdurna |
| Regeneron Healthcare Solutions, INC. | $346.20 | 2019-2025 | Evkeeza, Praluent |
| Alexion Pharmaceuticals, INC. | $343.00 | 2020-2025 | Strensiq |
| Inspire Medical Systems, INC. | $315.10 | 2023-2025 | Inspire |
| Beta Bionics, INC. | $278.56 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Pfizer INC. | $266.50 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $252.14 | 2020-2024 | Xifaxan, Trulance |
| Neurocrine Biosciences, INC. | $248.58 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $248.25 | 2020-2021 | |
| Mannkind Corporation | $243.48 | 2020-2024 | Afrezza |
| Eusa Pharma (US) LLC | $239.31 | 2022 | |
| Madrigal Pharmaceuticals | $208.38 | 2024-2025 | Rezdiffra, Resmetirom |
| Ultragenyx Pharmaceutical INC. | $96.40 | 2021-2024 | Crysvita |
| Ascendis Pharma Endocrinology INC | $93.09 | 2023-2025 | Yorvipath |
| Kowa Pharmaceuticals America, INC. | $89.26 | 2020-2023 | Livalo |
| Biohaven Pharmaceutical Holding Company LTD. | $89.00 | 2022 | |
| Kyowa Kirin, INC. | $72.41 | 2023 | Crysvita |
| Eisai INC. | $66.67 | 2019 | |
| Astellas Pharma US INC | $60.88 | 2024 | Veozah |
| Vifor Pharma, INC. | $60.25 | 2022 | |
| Amryt Pharma Holdings LTD | $53.89 | 2022-2023 | Mycapssa |
| Ionis Pharmaceuticals, INC. | $46.49 | 2025 | Tryngolza |
| Ascensia Diabetes Care US INC. | $43.42 | 2025 | |
| Chiesi USA, INC. | $40.36 | 2025 | Mycapssa |
| Glaxosmithkline, LLC. | $33.22 | 2019-2025 | Shingrix, Arexvy |
| Halozyme INC | $28.83 | 2023 | |
| Ibsa Pharma INC. | $28.76 | 2020-2021 | |
| Avion Pharmaceuticals | $27.01 | 2021-2023 | Balcoltra |
| Ipsen Biopharmaceuticals, INC | $26.63 | 2019 | |
| Becton, Dickinson and Company | $25.62 | 2020 | |
| Allergan, INC. | $19.43 | 2019 | |
| Ironwood Pharmaceuticals, INC | $16.17 | 2019 | |
| Rhythm Pharmaceuticals, INC. | $14.46 | 2025 | Imcivree |
| Arbor Pharmaceuticals, INC. | $12.44 | 2021 | |
| Nalpropion Pharmaceuticals LLC | $12.19 | 2019 | |
| Cequr Corporation | $5.69 | 2022 |
9 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$3,888.20 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sergio Rovner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.